Clinical Trial Update: Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 safety and immunogenicity trial of a recombinant Modified Vaccinia Virus Ankara (MVA)–based HIV vaccine. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Recombinant Modified Vaccinia Virus Ankara (MVA) HIV vaccine (Modified Vaccinia Virus Ankara-based HIV vaccine)

Snippet

Sponsor: Bavarian Nordic | Conditions: HIV Infections | Phase 1 | Status: COMPLETED